{"nctId":"NCT01646073","briefTitle":"Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","startDateStruct":{"date":"2012-08"},"conditions":["Plaque Psoriasis"],"count":425,"armGroups":[{"label":"Adalimumab","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: placebo"]}],"interventions":[{"name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of psoriasis for at least 6 months.\n* Must have stable plaque psoriasis for at least 2 months before screening and baseline visits.\n* Participant must have a Psoriasis Area Severity Index score greater than or equal to 10 at the baseline visit.\n* Participant must have moderate to severe plaque Psoriasis, defined by Body Surface Area involvement greater than or equal to 10% at the baseline visit.\n* Participant must have a Physicians Global Assessment of at least moderate disease at baseline visit.\n\nExclusion Criteria:\n\n* Diagnosis of other active skin diseases or skin infections.\n* Participant has known hypersensitivity to adalimumab or it excipients.\n* Participant has chronic recurring infections or active tuberculosis.\n* Participant has demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.\n* Participant is known to have immune deficiency or is immunocompromised.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12","description":"The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]","description":"The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI), other than Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]","description":"The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null},{"groupId":"OG001","value":"87.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]","description":"Psoriasis Area and Severity Index (PASI), is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.44","spread":"3.049"},{"groupId":"OG001","value":"-82.20","spread":"1.548"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]","description":"PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-91.39","spread":"14.423"},{"groupId":"OG001","value":"-91.07","spread":"19.028"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]","description":"The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"88.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]","description":"The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null},{"groupId":"OG001","value":"93.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"70.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"20.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"74.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":null},{"groupId":"OG001","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"35.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) of \"Clear\" [Period A]","description":"The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"25.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) of \"Clear\" [Period B]","description":"The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"45.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) of \"Clear\" or \"Minimal\" [Period A]","description":"The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":null},{"groupId":"OG001","value":"80.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) of \"Clear\" or \"Minimal\" [Period B]","description":"The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of \"0\" [Period A]","description":"The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of \"0\" [Period B]","description":"The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of \"0 or 1\" [Period A]","description":"The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"28.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of \"0 or 1\" [Period B]","description":"The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"37.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]","description":"Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"0.665"},{"groupId":"OG001","value":"4.22","spread":"0.332"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.913"},{"groupId":"OG001","value":"7.02","spread":"0.456"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]","description":"Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.20","spread":"8.351"},{"groupId":"OG001","value":"4.73","spread":"8.260"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":"12.661"},{"groupId":"OG001","value":"7.76","spread":"11.652"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":87},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","OROPHARYNGEAL PAIN","COUGH"]}}}